Accuray Incorporated (ARAY)
NASDAQ: ARAYHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ARAY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.22M
- EPS (TTM)
- -$5.60
- Dividend yield
- None
- 52-week range
- 2.05 – 45.20
- Day range
- 2.06 – 2.19
- Volume / Avg
- 111.53K / 201.35K
- Beta
- —
- Shares outstanding
- 3.00M
52-week range
ARAY stock today
Shares of Accuray (ARAY) finished lower on Nov 20 at $2.08, a drop of 2.12% or $0.045 per share, versus the S&P 500's 3.70% decline. Shares are 95.4% below their 52-week high of $45.20 and 1.2% above the 52-week low of $2.05, near the bottom of the past year's range. ARAY is up 153.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 97.6%.
Accuray has posted a net loss over the last twelve months (EPS of -$5.60), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Accuray
Company profileAccuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Stephen R. LaNeve MBA
- Headquarters
- Madison, WI
- Employees
- 809
- IPO year
- 2007
- Website
- accuray.com
Financial highlights
Full financialsIn fiscal 2026, Accuray generated $401.9 million in revenue, down 12.3% from fiscal 2025, its first annual decline since 2024. Accuray reported a net loss of $49.2 million, compared with a loss of $1.6 million a year earlier. Gross margin was 27.7% (down from 32.1%) and operating margin -6.6%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $401.95M | $458.50M | $446.55M | $447.61M | $429.91M |
| Growth | -12.34% | +2.68% | -0.24% | +4.12% | +8.48% |
| Net income | $-49.19M | $-1.59M | $-15.54M | $-9.28M | $-5.35M |
| EPS (diluted) | — | $-0.02 | $-0.16 | $-0.10 | $-0.06 |
Analyst forecast
ForecastConsensus (1 analysts)
none
- Strong buy 0
- Buy 0
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.18 vs —
ARAY news
All ARAY news- Accuray Incorporated Announces Results of 2026 Annual Meeting of StockholdersNasdaq
- Accuray Closes TCW Transaction, Strengthening Balance Sheet to Support Long-Term Value GrowthPR Newswire
- Accuray Reports Fiscal 2027 First Quarter Financial ResultsNasdaq
- Accuray Announces 1-for-40 Reverse Stock SplitPR Newswire
- Accuray Reports Fiscal 2027 First Quarter Financial ResultsPR Newswire
- Accuray Incorporated Reports Inducement Award Under NASDAQ Listing RulesPR Newswire
- Accuray to Report First Quarter Fiscal 2027 Financial Results on November 4, 2026PR Newswire
Accuray peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CNSYCerenome Inc. | 0.6301 | -10.29% | $6.16M | vs ARAY |
| NMTCNeuroOne Medical Technologies Corporation | 0.6521 | -3.38% | $5.94M | vs ARAY |
| BDMDBaird Medical Investment Holdings Ltd | 0.0897 | -12.91% | $5.07M | vs ARAY |
| ICUSeaStar Medical Holding Corporation | 0.935 | -10.95% | $4.97M | vs ARAY |
| WOKWORK Medical Technology Group LTD Class A | 1.10 | -5.13% | $4.90M | vs ARAY |
| SKYASkyAI Inc. | 2.18 | -45.50% | $7.82M | vs ARAY |
| INBSIntelligent Bio Solutions Inc. | 1.39 | -7.95% | $4.61M | vs ARAY |
| ICCMIceCure Medical Ltd. | 0.8006 | -19.71% | $4.45M | vs ARAY |
Indexes, lists and sector
Accuray stock FAQ
What is Accuray's stock price today?
ARAY last traded at $2.08 as of Nov 20, 4:00 PM EST, down 2.12% on the day. Prices are delayed at least 15 minutes.
Does Accuray pay a dividend?
No. Accuray does not currently pay a regular cash dividend.
Who is Accuray's CEO?
Mr. Stephen R. LaNeve MBA is the chief executive officer of Accuray Incorporated, which has about 809 employees.
Has ARAY ever split its stock?
Yes. The most recent ARAY stock split was a 1-for-40 split on Nov 9, 2026.
What is the ARAY 52-week high?
The 52-week high for ARAY is $45.20 and the 52-week low is $2.05. The stock is currently 95.4% below its high.